EIF4B

Across TCGA pan-cancer cohorts, EIF4B mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated EIF4B data layer compared with 26 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher EIF4B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated EIF4B expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, LSCC, and LUAD are the cancer types where EIF4B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	II,III,IV	0.653	0.362	.010	10	view →
LSCC	DFS	Median	II,III,IV	0.815	0.580	.025	9	view →
LUAD	DFS	Quartile	III,IV	1.000	0.438	.024	9	view →
UCEC	DFS	Quartile	III,IV	1.000	0.279	.027	8	view →
CCRCC	DFS	Median	All	0.637	0.866	.012	7	view →
HNSC	OS	Median	III,IV	1.000	0.946	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

EIF4B–PDAC (DFS)

Open the PDAC breakdown →